Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
PacBio (NASDAQ:PACB) began worldwide shipping of its SPRQ-Nx chemistry and multi-use SMRT Cells for the Revio HiFi platform, reducing sequencing costs by about 30% versus prior SPRQ chemistry.
The new consumables target a $345 list price per genome and enable sub-$300 HiFi genomes at scale, while AI-driven DeepConsensus and updated methylation models aim to improve accuracy, yield, and epigenetic insight.
PacBio (NASDAQ:PACB) announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York. A live webcast and 30-day replay will be available on the investor website.
Blank Bio announced a $7.2 million seed financing and a strategic collaboration with PacBio (NASDAQ:PACB) to advance RNA foundation models for precision oncology. Funding will support model development, pharma and diagnostic partnerships, and new long-read bulk RNA-seq datasets from up to 100 tumor samples.
PacBio (NASDAQ:PACB) announced the first major study from the HiFi Solves Sub-fertility Consortium in Asia Pacific, using HiFi long-read whole genome sequencing to investigate unexplained subfertility and recurrent pregnancy loss.
The multicenter study sequenced 84 individuals, finding clinically relevant genomic findings in about one in 10 couples and likely diagnostic variants in 4.8% of individuals, using a federated, cross-border data analysis framework.
PacBio (NASDAQ: PACB) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $37.2M with consumables $21.8M and instrument revenue $9.7M. GAAP gross profit was $12.8M and GAAP net loss was $8.3M. Ending cash and investments were $276.0M. Company completed sale of short-read assets for $48.1M, was selected by Basecamp Research for the Trillion Gene Atlas, and provided full-year 2026 revenue guidance of $165M–$175M.
PacBio (NASDAQ: PACB) and Lucid Genomics announced on April 21, 2026 a compatibility collaboration under PacBio's Compatible partner program. The partnership certifies Lucid Genomics' tertiary analysis platform for PacBio HiFi long-read sequencing, enabling validated workflows from alignment and variant calling to clinical interpretation and methylation analysis.
The integration aims to streamline analysis, reduce integration risk, and accelerate time-to-insight for clinical and research labs using PacBio systems.
PacBio (NASDAQ: PACB) will report first quarter 2026 financial results and host a conference call on Thursday, May 7, 2026 at 4:30 p.m. ET (1:30 p.m. PT). The call will be webcast and available on the company's investor website.
Live listen and replay access are provided via the investor site at https://investor.pacificbiosciences.com/, toll-free dial-in 1-888-349-0136, and international dial-in 1-412-317-0459.
PacBio (NASDAQ: PACB) and Covaris announced a joint extraction-to-library workflow enabling HiFi long-read sequencing from FFPE tumor samples, integrating Covaris truXTRAC FFPE extraction with PacBio Kinnex library prep and Revio sequencing.
In studies across brain, kidney and uterine tumors the workflow produced >100 million HiFi reads per sample, mean read lengths of 750–1,500 bp, >11,000 structural variants and ~5 million small variants per sample, with ~60% of variants phased into haplotypes.
PacBio (NASDAQ: PACB) announced that Basecamp Research selected PacBio HiFi sequencing on the Revio system with SPRQ-Nx chemistry to power the Trillion Gene Atlas.
The collaboration will generate approximately 100,000 deeply sequenced samples from over 31 countries across 5 continents, creating the largest high-fidelity metagenomic dataset assembled to date.
PacBio (NASDAQ: PACB) appointed Christopher Gibson, Ph.D., to its Board of Directors on March 5, 2026. Dr. Gibson co-founded and chairs Recursion (NASDAQ: RXRX) and brings experience building AI-driven, high-dimensional biology platforms that integrate automation, sequencing-scale data, and machine learning to accelerate discovery.
This appointment aims to strengthen PacBio’s ability to develop data tools and advanced analytics for HiFi long-read sequencing datasets.